Current problems in cancer. Case reports最新文献_第3页

Revisiting the Whipple procedure in chondrosarcoma metastasis to the pancreas 再次探讨胰腺软骨肉瘤转移的惠普尔手术

IF 0.2

Current problems in cancer. Case reports Pub Date : 2024-11-16 DOI: 10.1016/j.cpccr.2024.100333

Joseph S Lim , Daniel Zeter , Paul Murdock , Joseph Saad , Houssam Osman , Joseph Buell , Dhiresh Rohan Jeyarajah

{"title":"Revisiting the Whipple procedure in chondrosarcoma metastasis to the pancreas","authors":"Joseph S Lim , Daniel Zeter , Paul Murdock , Joseph Saad , Houssam Osman , Joseph Buell , Dhiresh Rohan Jeyarajah","doi":"10.1016/j.cpccr.2024.100333","DOIUrl":"10.1016/j.cpccr.2024.100333","url":null,"abstract":"<div><h3>Introduction</h3><div>Chondrosarcoma is the second most common primary bone cancer with the lungs being the primary site of metastasis. Pancreatic metastases can occur, but their rarity makes management challenging.</div></div><div><h3>Presentation of case</h3><div>A 27-year-old female with a past medical history of childhood chondrosarcoma of her left tibia presented with metastatic chondrosarcoma of the pancreas five years later. The patient underwent an upfront Whipple procedure with positive margins. Upon recovery, her oncology team recommended watchful waiting. One year later, she presented to the emergency department with coffee ground emesis and diffuse abdominal pain. A computed tomography scan showed a large recurrent mass at the pancreatic remnant concerning for local recurrence. Upper endoscopy found active bleeding near the gastrojejunostomy anastomosis with no ulcers as well as portal hypertensive gastropathy. After discussing these findings, the patient ultimately declined any further treatment, and she was discharged to hospice.</div></div><div><h3>Discussion</h3><div>This is the second reported case of a Whipple procedure for metastatic chondrosarcoma, and first with positive margins (R1). It appears that chondrosarcoma metastasis to the pancreas requiring Whipple procedure is associated with poor outcomes. This unfortunate result is further compounded by the lack of neoadjuvant or adjuvant chemotherapy or radiation in the setting of R1 resection.</div></div><div><h3>Conclusion</h3><div>Upfront Whipple procedure in metastatic chondrosarcoma at high risk for R1 resection should be considered with neoadjuvant radiation Adjuvant radiation can be considered if there are positive margins.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"17 ","pages":"Article 100333"},"PeriodicalIF":0.2,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142744469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Atypical presentation of lung adenocarcinoma as cardiac tamponade and venous thromboembolism: A case report

IF 0.2

Current problems in cancer. Case reports Pub Date : 2024-11-13 DOI: 10.1016/j.cpccr.2024.100331

Amit Kumar, Sandeep Garg, Praveen Bharti, Manidipa Mondal

引用次数: 0

Acquired lipodystrophy following use of pembrolizumab 使用 Pembrolizumab 后获得性脂肪营养不良

IF 0.2

Current problems in cancer. Case reports Pub Date : 2024-10-31 DOI: 10.1016/j.cpccr.2024.100332

Maya Weitzen , Marcus DaSilva Goncalves , Shaheer Khan , Alexander Barbaro , Richard Carvajal , Keyur Thakar

{"title":"Acquired lipodystrophy following use of pembrolizumab","authors":"Maya Weitzen , Marcus DaSilva Goncalves , Shaheer Khan , Alexander Barbaro , Richard Carvajal , Keyur Thakar","doi":"10.1016/j.cpccr.2024.100332","DOIUrl":"10.1016/j.cpccr.2024.100332","url":null,"abstract":"<div><div>This case report details a 65-year-old female with Hashimoto's hypothyroidism and stage III melanoma who developed acquired generalized lipodystrophy (AGL), a rare immune-mediated adverse event, following pembrolizumab treatment. The patient was initially treated with nivolumab but was switched to pembrolizumab after developing optic neuritis. After starting pembrolizumab, the patient experienced significant weight loss and lipoatrophy in the face, thighs, and buttocks, alongside hypertrophy of the fat pads in her axillae, supraclavicular, and suprapubic areas. The patient also exhibited symptoms of marked insulin resistance and hypertriglyceridemia, indicative of AGL. Pembrolizumab treatment was discontinued after the patient developed additional side effects including hepatitis, hypophysitis, and thyroiditis, and the patient was commenced on steroid therapy. The patients insulin resistance and hypertriglyceridemia subsequently improved. Genetic sequencing excluded a genetic cause for her lipodystrophy. This is the fourth case of a patient developing AGL following administration of pembrolizumab, and the third for advanced melanoma. Since pembrolizumab administration for treatment of advanced melanoma is becoming more common, it necessitates clinician awareness to potential, rare complications not commonly defined in initial clinical trials.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"16 ","pages":"Article 100332"},"PeriodicalIF":0.2,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142658942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adeno-squamous carcinoma of bartholin gland: Challenges in diagnosis and management of a less known vulvar cancer – A case report 巴氏腺鳞癌：鲜为人知的外阴癌的诊断和治疗难题 - 病例报告

IF 0.2

Current problems in cancer. Case reports Pub Date : 2024-10-18 DOI: 10.1016/j.cpccr.2024.100330

Sarita Kumari , Ruchi Rathore , Abhinav Singhal , Haritha Maddirala , Sandeep Mathur , Neerja Bhatla

引用次数: 0

Prolonged survival in postoperative recurrent EGFR-L858R NSCLC: A 24-year case report 延长 EGFR-L858R NSCLC 术后复发患者的生存期：长达 24 年的病例报告

IF 0.2

Current problems in cancer. Case reports Pub Date : 2024-10-18 DOI: 10.1016/j.cpccr.2024.100329

Yoshihiro Go , Chinatsu Yoshizaki , Yuki Yoshida , Shiho Nohmi , Rui Kusakado , Yuichiro Saito , Kensuke Izumizaki , Takafumi Ogawa , Takashi Suzuki , Fumihiro Yamaguchi

引用次数: 0

Refractory chronic lymphocytic leukemia with concomitant extramedullary multiple myeloma with lymph node involvement 难治性慢性淋巴细胞白血病合并淋巴结受累的髓外多发性骨髓瘤

IF 0.2

Current problems in cancer. Case reports Pub Date : 2024-10-18 DOI: 10.1016/j.cpccr.2024.100324

Piotr Jachimowski , Łukasz Ciulkiewicz , Bogna Ziarkiewicz-Wróblewska , Laretta Grabowska-Derlatka , Grzegorz Basak , Mateusz Ziarkiewicz

引用次数: 0

Anaphylaxis from filgrastim prophylaxis within the same day of chemotherapy: A case report 化疗当天服用非格司亭预防药物引发过敏性休克：病例报告

IF 0.2

Current problems in cancer. Case reports Pub Date : 2024-10-17 DOI: 10.1016/j.cpccr.2024.100328

Suluck Soontaros , Supaporn Wongduang , Nattawut Leelakanok

{"title":"Anaphylaxis from filgrastim prophylaxis within the same day of chemotherapy: A case report","authors":"Suluck Soontaros , Supaporn Wongduang , Nattawut Leelakanok","doi":"10.1016/j.cpccr.2024.100328","DOIUrl":"10.1016/j.cpccr.2024.100328","url":null,"abstract":"<div><h3>Introduction</h3><div>Filgrastim is recommended to be used 24–72 h after the last dose of chemotherapy for the prophylaxis of febrile neutropenia. However, several studies demonstrate the efficacy and safety of the use of filgrastim within the same day of the last dose of chemotherapy.</div></div><div><h3>Case presentation</h3><div>We presented a patient with state IIIC immature teratoma at her right ovary who was treated with the BEP regimen. She received 10 doses of filgrastim per BEP cycle to prevent febrile neutropenia. On the first BEP cycle, the first dose of filgrastim was used within 24 h after the last chemotherapy dose and dyspnea was developed. On the second cycle of BEP, filgrastim was still used as the same-day regimen. One hour after the first dose of filgrastim, anaphylaxis occurred and the patient was treated appropriately. The second dose of filgrastim can be rechallenged successfully and filgrastim can be finished without any adverse events. On the third and fourth cycles of BEP, filgrastim was used as the next-day regimen (interval longer than 24 h). There were no adverse events that occurred during the use of filgrastim.</div></div><div><h3>Conclusion</h3><div>The residual chemotherapy may increase the risk of anaphylaxis induced by filgrastim via a non-IgE-mediated mechanism in this case patient.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"16 ","pages":"Article 100328"},"PeriodicalIF":0.2,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142534679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Refractory IgM AL amyloidosis with massive soft tissue tumors: Rescue with zanubrutinib. A case report 难治性IgM AL淀粉样变性伴巨大软组织肿瘤：扎努布替尼的救治。病例报告

IF 0.2

Current problems in cancer. Case reports Pub Date : 2024-10-12 DOI: 10.1016/j.cpccr.2024.100325

Piotr Jachimowski , Łukasz Ciulkiewicz , Mateusz Ziarkiewicz , Bogna Ziarkiewicz-Wróblewska , Marta Legatowicz-Koprowska , Krzysztof Jamroziak

引用次数: 0

Unusual presentation of melena due to duodenal metastasis from primary lung adenocarcinoma 原发性肺腺癌十二指肠转移引起的血性腹泻的异常表现

IF 0.2

Current problems in cancer. Case reports Pub Date : 2024-10-11 DOI: 10.1016/j.cpccr.2024.100326

Gülden Bilican , Serkan Dumanlı , Ercan Yıldırım , Ali Karataş , Ayşenur Sert , Ozan Yazıcı

引用次数: 0

Definitive chemoradiotherapy with Carboplatin Plus Paclitaxel for Unresectable Locally Advanced Thymic Carcinoma: A case series 用卡铂加紫杉醇对无法切除的局部晚期胸腺癌进行确定性化放疗：一个病例系列

IF 0.2

Current problems in cancer. Case reports Pub Date : 2024-09-17 DOI: 10.1016/j.cpccr.2024.100323

Koichiro Nozaki, Satoshi Watanabe, Ryo Yamazaki, Masashi Arita, Toshiaki Kikuchi

{"title":"Definitive chemoradiotherapy with Carboplatin Plus Paclitaxel for Unresectable Locally Advanced Thymic Carcinoma: A case series","authors":"Koichiro Nozaki, Satoshi Watanabe, Ryo Yamazaki, Masashi Arita, Toshiaki Kikuchi","doi":"10.1016/j.cpccr.2024.100323","DOIUrl":"10.1016/j.cpccr.2024.100323","url":null,"abstract":"<div><h3>Objectives</h3><p>Thymic carcinoma (TC) is rare. There is no evidence regarding the treatment strategies for unresectable locally advanced thymic carcinomas. Definitive chemoradiotherapy may treat this condition. However, an appropriate concurrent chemotherapy with radiotherapy has not yet been established.</p></div><div><h3>Materials and methods</h3><p>We present three cases of locally advanced thymic carcinoma treated with definitive chemoradiotherapy using carboplatin and paclitaxel.</p></div><div><h3>Results</h3><p>Three patients aged 74–81 with Masaoka stage III thymic carcinoma were included. One patient was a woman, and two patients were men. All patients received weekly carboplatin (area under the curve, 2) plus paclitaxel (40 mg m<sup>-12</sup>) and concurrent radiotherapy (60 Gy). One patient experienced an adverse event of grade 3 radiation pneumonitis after chemoradiotherapy, but the three patients completed chemoradiotherapy with minor adverse events during treatment. Progression-free survival after chemoradiotherapy was 59+, 24+, and 16+ months, respectively; all patients were alive.</p></div><div><h3>Conclusion</h3><p>Definitive concurrent chemoradiotherapy with weekly carboplatin plus paclitaxel may be effective for treating unresectable locally advanced thymic carcinomas.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"16 ","pages":"Article 100323"},"PeriodicalIF":0.2,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621924000462/pdfft?md5=fa9d2b295942b0387d1f7cb0dacef82f&pid=1-s2.0-S2666621924000462-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142272642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0